Yesterday, Orient Gene issued a report, announcing that the company has successfully completed the acquisition of 100% of Beijing Shouyi Biochem. This acquisition is intended to structure the domestic market and extend product lines of in vitro diagnostics.

Founded in 1998, Shouyi Biochem is a biomedical enterprise controlled by Capital Medical University. Its main business is in vitro diagnostic reagent industry, also including medical equipment, pharmaceutical product research and development, production, sales and technical services.

Orient Gene's business is dominated by overseas markets. In 2020, overseas sales accounted for approximately 95% in total sales. Due to the significant sales performance of COVID-19 related testing reagents, Orient Gene's net profit in 2020 achieved a substantial increase of 2082%.

Through this acquisition of Shouyi Biochem, Orient Gene is gradually increasing its efforts to lay out the industrial chain and the domestic market. In the future, Orient Gene will fully integrate domestic and overseas resources, and support the development of medical and health industry with internationally leading products and services.